|
28 Aug 2019 |
Arvinas Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of ARV-471, an Estrogen Receptor-Targeting PROTAC® Protein Degrader
|
|
28 Aug 2019 |
Ascletis Received IND Approval for its NASH Drug
|
|
28 Aug 2019 |
Kyowa Kirin Announces FDA Approval of NOURIANZTM (istradefylline) for Use in Parkinson’s Disease
|
|
28 Aug 2019 |
Breztri Aerosphere Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease
|
|
27 Aug 2019 |
Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I Trial of ONC206
|
|
27 Aug 2019 |
Santhera Announces Publication by ReveraGen of Positive Phase IIa-Extension Study Results with Vamorolone in Patients with Duchenne Muscular Dystrophy
|
|
27 Aug 2019 |
Basilea announces completion of patient enrolment in phase 1 study with oral BAL101553 in brain cancer
|
|
27 Aug 2019 |
Trovagene Presents Positive Clinical Data from Ongoing Phase 2 Study of Onvansertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
|
|
27 Aug 2019 |
InDex Pharmaceuticals Meets Primary Endpoint in the Phase IIb Study CONDUCT with Cobitolimod in Ulcerative Colitis
|
|
27 Aug 2019 |
LEO Pharma Files IND Application to FDA for a Clinical Study of JW1601/LP0190 in the US
|
|
24 Aug 2019 |
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis
|
|
23 Aug 2019 |
Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with Immune Thrombocytopenia (ITP) in China
|
|
23 Aug 2019 |
Retrophin Announces Topline Results from Phase 3 FORT Study of Fosmetpantotenate in Patients with PKAN
|
|
22 Aug 2019 |
Snap Bio's Lead Candidate Overcomes Resistance of Approved Drugs for Liver Cancer
|
|
22 Aug 2019 |
Merck Highlights New Data from Leading Lung Cancer Clinical Development Program at the IASLC 2019 World Conference on Lung Cancer
|
|
22 Aug 2019 |
BeiGene Announces U.S. FDA Acceptance and Grant of Priority Review for its New Drug Application of Zanubrutinib in Patients with Relapsed/Refractory Mantle Cell Lymphoma
|
|
22 Aug 2019 |
U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer
|
|
22 Aug 2019 |
ViiV Healthcare Reports Positive Phase III Study Results of Investigational, Long-acting, Injectable HIV-Treatment Regimen Administered Every Two Months
|
|
22 Aug 2019 |
Roxadustat approved in China for the treatment of anaemia in non-dialysis-dependent patients with chronic kidney disease
|
|
21 Aug 2019 |
Aptinyx Presents Data Demonstrating Positive Activity of NYX-458 on Cognitive Performance and Biomarkers in a Preclinical Model of Head Injury
|
|
21 Aug 2019 |
Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study ACELARATE Has Been Suspended Following a Prespecified Futility Analysis
|
|
21 Aug 2019 |
GSK submits first regulatory application for daprodustat in Japan for patients with renal anaemia due to chronic kidney disease
|
|
21 Aug 2019 |
Cassiopea Announces FDA Submission of New Drug Application for Clascoterone Cream 1%, the First New Mechanism of Action for Acne in Nearly 40 Years
|
|
20 Aug 2019 |
Outlook Therapeutics Completes Patient Enrollment for NORSE 1 a Phase 3 Clinical Trial for ONS-5010 in Wet AMD
|
|
20 Aug 2019 |
Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
|
